TrialFrontiers in immunology2025

Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60-70 years in Shanghai, China.

Jing Qiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.